Published • loading... • Updated
IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit
Investors who bought Immutep ADRs may seek lead plaintiff status in a class action alleging misleading statements about the TACTI-004 trial.
- Rosen Law Firm and The Schall Law Firm announced a class action against Immutep Ltd. for purchasers of ADRs between March 24, 2025, and March 12, 2026, alleging securities fraud.
- The lawsuit alleges Immutep concealed internal data regarding the TACTI-004 trial of eftilagimod alfa , knowing the treatment would fail to meet primary efficacy endpoints.
- Despite claiming "strong operational progress" in a Form-K filing on January 30, 2026, the company allegedly misled investors; when true results entered the market, shareholders claimed financial damages.
- Shareholders who purchased securities during the Class Period may be entitled to compensation without upfront fees through a contingency arrangement, though the class has not yet been certified.
- Interested investors must move the Court by July 6, 2026, to serve as lead plaintiff; those seeking participation can contact Rosen Law Firm or The Schall Law Firm online.
Insights by Ground AI
45 Articles
45 Articles
Coverage Details
Total News Sources45
Leaning Left7Leaning Right3Center21Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
L 22%
C 68%
Factuality
To view factuality data please Upgrade to Premium
